CM
ADMA icon

Castleark Management’s ADMA Biologics ADMA Stock Holding History

Castleark Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-456,266
Closed -$9.05M – 277
2025
Q1 		$9.05M Buy
456,266
+69,900
+18% +$1.21M 0.31% 43
2024
Q4 		$6.63M Sell
386,366
-306,600
-44% -$5.77M 0.23% 100
2024
Q3 		$13.9M Sell
692,966
-145,120
-17% -$2.26M 0.56% 31
2024
Q2 		$9.37M Buy
838,086
+19,976
+2% +$168K 0.38% 45
2024
Q1 		$5.4M Buy
+818,110
New +$4.47M 0.22% 105

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Castleark Management's ADMA Position: Q2 2025 in Review

Castleark Management sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 456,266 shares — an estimated $9.05M sold.

Castleark Management first reported a position in ADMA in Q1 2024 and held it in 5 quarters. The position peaked at $13.9M in Q3 2024. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • Castleark Management reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
  • Castleark Management sold 456,266 ADMA Biologics shares in Q2 2025, an estimated $9.05M.
  • Castleark Management first reported a position in ADMA Biologics in Q1 2024 and held it in 5 quarters.
  • Castleark Management's ADMA Biologics position peaked at $13.9M in Q3 2024.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on Castleark Management's 13F filing for Q2 2025, filed 18 Aug 2025.